We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
SWISS LAW AND TAX
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
On 28 December 2023, Danstar Ferment AG, a Swiss subsidiary of Canadian multi-national, Lallemand Inc., has successfully completed the acquisition of Swiss based Evolva AG, subsidiary of SIX listed Evolva Holding SA.
Fangda Carbon New Material Co., Ltd., an integrated carbon materials producer in in the People's Republic of China with diversified product offerings, including graphite electrodes, carbon blocks, isostatic graphite and iron ore concentrates, sold 22m global depositary receipts (GDRs) at an offer price of USD 8.63 per GDR and listed on 15 March 2023 a total number of 57'089'555 GDRs on the SIX Swiss Exchange (ISIN: US30712D1072, ticker: FDCB), thereby successfully tapping the Swiss capital market and raising gross proceeds of approximately USD 190m. Each GDR represents ten A shares of Fangda, which in turn are listed on the Shanghai Stock Exchange (600516.SH).
VISCHER advised Oberland Capital Management LLC on its financing agreement with the Helsinn Group.
Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies.
On 28 July 2022, Ningbo Shanshan Co. raised USD 310.5m through GDRs issuance and listing on the SIX Swiss Exchange.
VISCHER has advised ADVANZ PHARMA, a specialty pharmaceutical company headquartered in London, on all Swiss legal aspects of its USD 450m acquisition of the ex-US business of Intercept Pharmaceuticals, spanning from due diligence to transactional document advice.
Funds advised by Gilde Buy Out Partners, a leading European private equity investor, completed the investment in MBK Fincom ("MBK" or the "Company"), alongside the founders and management which are reinvesting in the business....
A fund advised by AFINUM Management AG signed on 8 October 2021 a share purchase agreement with exceet Group AG, a company of the exceet Group, to buy exceet Group's portfolio company GS Swiss PCB AG.
The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The transaction was completed on August 5, 2021.
Dermavant Sciences announced that the company has entered into a USD 160m revenue interest purchase and sale agreement for its investigational product tapinarof with three participants.
Displaying results 1 to 10 out of 61
